Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A T-helper 1/interferon- gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer.

Dizier B, Callegaro A, Debois M, Dreno B, Hersey P, Gogas HJ, Kirkwood JM, Vansteenkiste JF, Sequist LV, Atanackovic D, Goeman J, van Houwelingen H, Salceda S, Wang F, Therasse P, Debruyne C, Spiessens B, Brichard VG, Louahed J, Ulloa-Montoya F.

Clin Cancer Res. 2019 Nov 15. pii: clincanres.3717.2018. doi: 10.1158/1078-0432.CCR-18-3717. [Epub ahead of print]

PMID:
31732522
2.

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.

Baurain JF, Robert C, Mortier L, Neyns B, Grange F, Lebbe C, Ulloa-Montoya F, De Sousa Alves PM, Gillet M, Louahed J, Jarnjak S, Lehmann FF.

ESMO Open. 2018 Jul 25;3(5):e000384. doi: 10.1136/esmoopen-2018-000384. eCollection 2018.

3.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM.

Lancet Oncol. 2018 Jul;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. Epub 2018 Jun 13.

PMID:
29908991
4.

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature.

Grob JJ, Mortier L, D'Hondt L, Grange F, Baurain JF, Dréno B, Lebbe C, Robert C, Dompmartin A, Neyns B, Gillet M, Louahed J, Jarnjak S, Lehmann FF.

ESMO Open. 2017 Nov 14;2(5):e000203. doi: 10.1136/esmoopen-2017-000203. eCollection 2017.

5.

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.

Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo P, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhoutte N, Salaun B, Gillet M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF.

ESMO Open. 2016 Aug 8;1(4):e000068. eCollection 2016.

6.

The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.

Thongprasert S, Yang PC, Lee JS, Soo R, Gruselle O, Myo A, Louahed J, Lehmann FF, Brichard VG, Coche T.

Lung Cancer. 2016 Nov;101:137-144. doi: 10.1016/j.lungcan.2016.09.006. Epub 2016 Oct 5.

7.

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study.

Pujol JL, De Pas T, Rittmeyer A, Vallières E, Kubisa B, Levchenko E, Wiesemann S, Masters GA, Shen R, Tjulandin SA, Hofmann HS, Vanhoutte N, Salaun B, Debois M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF.

J Thorac Oncol. 2016 Dec;11(12):2208-2217. doi: 10.1016/j.jtho.2016.08.120. Epub 2016 Aug 17.

8.

Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients.

Pan SH, Su KY, Spiessens B, Kusuma N, Delahaye NF, Gruselle O, Myo A, de Creus A, Louahed J, Chang GC, Yu SL, Yang PC.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e212-e223. doi: 10.1111/ajco.12586. Epub 2016 Aug 12.

PMID:
27519286
9.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N.

Lancet Oncol. 2016 Jun;17(6):822-835. doi: 10.1016/S1470-2045(16)00099-1. Epub 2016 Apr 27.

PMID:
27132212
10.

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors.

Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF.

Breast Cancer Res Treat. 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18.

PMID:
26993131
11.

A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer.

Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF.

Breast Cancer Res Treat. 2016 Apr;156(2):301-10. doi: 10.1007/s10549-016-3750-y. Epub 2016 Mar 14.

PMID:
26975189
12.

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors.

Gérard C, Baudson N, Ory T, Segal L, Louahed J.

J Immunother. 2015 Oct;38(8):311-20. doi: 10.1097/CJI.0000000000000095.

13.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.

Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M, Douillard JY, Fasola G, Potter V, Taylor P, Bosquée L, Scheubel R, Jarnjak S, Debois M, de Sousa Alves P, Louahed J, Brichard VG, Lehmann FF.

J Thorac Oncol. 2015 Oct;10(10):1458-67. doi: 10.1097/JTO.0000000000000653.

14.

Development of a Quantitative Real-Time RT-PCR Assay for the Detection of MAGE-A3-Positive Tumors.

Gruselle O, Coche T, Louahed J.

J Mol Diagn. 2015 Jul;17(4):382-91. doi: 10.1016/j.jmoldx.2015.03.008. Epub 2015 May 15.

PMID:
25986000
15.

Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.

Gérard C, Baudson N, Ory T, Louahed J.

PLoS One. 2014 May 15;9(5):e94883. doi: 10.1371/journal.pone.0094883. eCollection 2014.

16.

MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, Louahed J, Chen W, Woods K, Cebon JS.

Cancer Immunol Res. 2014 Apr;2(4):351-60. doi: 10.1158/2326-6066.CIR-13-0181. Epub 2014 Jan 17.

17.

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, Maio M, Testori A, Dorval T, Grob JJ, Becker JC, Spatz A, Eggermont AM, Louahed J, Lehmann FF, Brichard VG, Keilholz U.

J Clin Oncol. 2013 Jul 1;31(19):2413-20. doi: 10.1200/JCO.2012.43.7111. Epub 2013 May 28.

PMID:
23715572
18.

Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WH, Eggermont AM, Vansteenkiste J, Brichard VG.

J Clin Oncol. 2013 Jul 1;31(19):2388-95. doi: 10.1200/JCO.2012.44.3762. Epub 2013 May 28.

PMID:
23715562
19.

Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy.

Brichard VG, Louahed J, Clay TM.

J Immunother. 2013 Feb;36(2):79-81. doi: 10.1097/CJI.0b013e3182829747. No abstract available.

PMID:
23377666
20.

Antibody production by injection of living cells expressing non self antigens as cell surface type II transmembrane fusion protein.

Nizet Y, Gillet L, Schroeder H, Lecuivre C, Louahed J, Renauld JC, Gianello P, Vanderplasschen A.

J Immunol Methods. 2011 Mar 31;367(1-2):70-7. doi: 10.1016/j.jim.2011.02.007. Epub 2011 Feb 24.

PMID:
21354163
21.

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.

Gajewski TF, Louahed J, Brichard VG.

Cancer J. 2010 Jul-Aug;16(4):399-403. doi: 10.1097/PPO.0b013e3181eacbd8. Review.

PMID:
20693853
22.

IL-9 promotes IL-13-dependent paneth cell hyperplasia and up-regulation of innate immunity mediators in intestinal mucosa.

Steenwinckel V, Louahed J, Lemaire MM, Sommereyns C, Warnier G, McKenzie A, Brombacher F, Van Snick J, Renauld JC.

J Immunol. 2009 Apr 15;182(8):4737-43. doi: 10.4049/jimmunol.0801941.

23.

The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.

Minne A, Louahed J, Mehauden S, Baras B, Renauld JC, Vanbever R.

Immunology. 2007 Nov;122(3):316-25. Epub 2007 May 22.

24.

IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells.

Steenwinckel V, Louahed J, Orabona C, Huaux F, Warnier G, McKenzie A, Lison D, Levitt R, Renauld JC.

J Immunol. 2007 Mar 1;178(5):3244-51.

25.

B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic mice.

Arras M, Louahed J, Simoen V, Barbarin V, Misson P, van den Brûle S, Delos M, Knoops L, Renauld JC, Lison D, Huaux F.

Am J Respir Cell Mol Biol. 2006 May;34(5):573-80. Epub 2006 Jan 19.

PMID:
16424385
26.

IL-9 promotes but is not necessary for systemic anaphylaxis.

Knoops L, Louahed J, Van Snick J, Renauld JC.

J Immunol. 2005 Jul 1;175(1):335-41.

27.

IL-9 protects against bleomycin-induced lung injury: involvement of prostaglandins.

Arras M, Louahed J, Heilier JF, Delos M, Brombacher F, Renauld JC, Lison D, Huaux F.

Am J Pathol. 2005 Jan;166(1):107-15.

28.
29.

Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice.

Lombry C, Marteleur A, Arras M, Lison D, Louahed J, Renauld JC, Préat V, Vanbever R.

Pharm Res. 2004 Jan;21(1):127-35.

PMID:
14984267
30.

MAP kinase activation by interleukin-9 in lymphoid and mast cell lines.

Demoulin JB, Louahed J, Dumoutier L, Stevens M, Renauld JC.

Oncogene. 2003 Mar 27;22(12):1763-70.

PMID:
12660812
31.

CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I.

Louahed J, Struyf S, Demoulin JB, Parmentier M, Van Snick J, Van Damme J, Renauld JC.

Eur J Immunol. 2003 Feb;33(2):494-501.

32.

A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction.

Zhou Y, Shapiro M, Dong Q, Louahed J, Weiss C, Wan S, Chen Q, Dragwa C, Savio D, Huang M, Fuller C, Tomer Y, Nicolaides NC, McLane M, Levitt RC.

Novartis Found Symp. 2002;248:150-65; discussion 165-70, 277-82.

PMID:
12568493
33.

Isolation of Ixodes ricinus salivary gland mRNA encoding factors induced during blood feeding.

Leboulle G, Rochez C, Louahed J, Ruti B, Brossard M, Bollen A, Godfroid E.

Am J Trop Med Hyg. 2002 Mar;66(3):225-33.

PMID:
12139212
34.

Characterization of a calcium-activated chloride channel as a shared target of Th2 cytokine pathways and its potential involvement in asthma.

Zhou Y, Dong Q, Louahed J, Dragwa C, Savio D, Huang M, Weiss C, Tomer Y, McLane MP, Nicolaides NC, Levitt RC.

Am J Respir Cell Mol Biol. 2001 Oct;25(4):486-91.

PMID:
11694454
35.

Interleukin 9 promotes influx and local maturation of eosinophils.

Louahed J, Zhou Y, Maloy WL, Rani PU, Weiss C, Tomer Y, Vink A, Renauld J, Van Snick J, Nicolaides NC, Levitt RC, Haczku A.

Blood. 2001 Feb 15;97(4):1035-42.

PMID:
11159534
36.

Role of insulin receptor substrate-2 in interleukin-9-dependent proliferation.

Demoulin JB, Grasso L, Atkins JM, Stevens M, Louahed J, Levitt RC, Nicolaides NC, Renauld JC.

FEBS Lett. 2000 Oct 6;482(3):200-4.

37.

IL-9 expression by human eosinophils: regulation by IL-1beta and TNF-alpha.

Gounni AS, Nutku E, Koussih L, Aris F, Louahed J, Levitt RC, Nicolaides NC, Hamid Q.

J Allergy Clin Immunol. 2000 Sep;106(3):460-6.

PMID:
10984364
38.

Interleukin-9 upregulates mucus expression in the airways.

Louahed J, Toda M, Jen J, Hamid Q, Renauld JC, Levitt RC, Nicolaides NC.

Am J Respir Cell Mol Biol. 2000 Jun;22(6):649-56.

PMID:
10837360
40.

Interleukin-9-induced expression of M-Ras/R-Ras3 oncogene in T-helper clones.

Louahed J, Grasso L, De Smet C, Van Roost E, Wildmann C, Nicolaides NC, Levitt RC, Renauld JC.

Blood. 1999 Sep 1;94(5):1701-10.

PMID:
10477695
41.

IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice.

Dong Q, Louahed J, Vink A, Sullivan CD, Messler CJ, Zhou Y, Haczku A, Huaux F, Arras M, Holroyd KJ, Renauld JC, Levitt RC, Nicolaides NC.

Eur J Immunol. 1999 Jul;29(7):2130-9.

42.

Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction.

Richard M, Louahed J, Demoulin JB, Renauld JC.

Blood. 1999 Jun 15;93(12):4318-27.

PMID:
10361130
43.

Murine adseverin (D5), a novel member of the gelsolin family, and murine adseverin are induced by interleukin-9 in T-helper lymphocytes.

Robbens J, Louahed J, De Pestel K, Van Colen I, Ampe C, Vandekerckhove J, Renauld JC.

Mol Cell Biol. 1998 Aug;18(8):4589-96.

44.

Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice.

Godfraind C, Louahed J, Faulkner H, Vink A, Warnier G, Grencis R, Renauld JC.

J Immunol. 1998 Apr 15;160(8):3989-96.

45.

Role of interleukin-10 in the lung response to silica in mice.

Huaux F, Louahed J, Hudspith B, Meredith C, Delos M, Renauld JC, Lison D.

Am J Respir Cell Mol Biol. 1998 Jan;18(1):51-9.

PMID:
9448045
46.

Cocaine induces apoptosis in cortical neurons of fetal mice.

Nassogne MC, Louahed J, Evrard P, Courtoy PJ.

J Neurochem. 1997 Jun;68(6):2442-50.

47.

Differential activity of dexamethasone on IL-2-, IL-4-, or IL-9-induced proliferation of murine factor-dependent T cell lines.

Louahed J, Renauld JC, Demoulin JB, Baughman G, Bourgeois S, Sugamura K, Van Snick J.

J Immunol. 1996 May 15;156(10):3704-10.

PMID:
8621905
48.

IL-9 induces expression of granzymes and high-affinity IgE receptor in murine T helper clones.

Louahed J, Kermouni A, Van Snick J, Renauld JC.

J Immunol. 1995 May 15;154(10):5061-70.

PMID:
7730612
49.

Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis.

Renauld JC, Kermouni A, Vink A, Louahed J, Van Snick J.

J Leukoc Biol. 1995 Mar;57(3):353-60. Review.

PMID:
7884304
50.

Interleukin-9 is a major anti-apoptotic factor for thymic lymphomas.

Renauld JC, Vink A, Louahed J, Van Snick J.

Blood. 1995 Mar 1;85(5):1300-5.

PMID:
7858260

Supplemental Content

Loading ...
Support Center